Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elpipodect in Acute Schizophrenia
NCT04624243Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Primary completion
- Jun 2024
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of elpipodect in schizophrenia (5 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Positive and Negative Syndrome Scale Total Score at 6 weeks, Number of Participants Who Experience One or More Adverse Events at 6 weeks and 1 more. Started Dec 2020; status: completed.
02
Drugs
elpipodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04624243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624243.